Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination

Journal of General Virology

Volumn 96, Issue 11, 2015, Pages 3265-3279

  Slon Campos, J L ^a   Poggianella, M ^a   Marchese, S ^a   Bestagno, M ^a   Burrone, O R ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; DNA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; DENGUE VACCINE; PROTEIN TRANSLOCASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; CROSS REACTION; CYTOFLUOROMETRY; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 4; DIMERIZATION; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOPRECIPITATION; MAMMAL CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECRETION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CLASSIFICATION; DENGUE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; SEROTYPE; VIROLOGY;

ANIMALS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSLOCATION SYSTEMS; PROTEIN TRANSPORT; SEROGROUP; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 84946866068     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/jgv.0.000278     Document Type: Article

References (86)

1. Allison, S. L., Schalich, J., Stiasny, K., Mandl, C. W. & Heinz, F. X. (2001). Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75, 4268-4275.
2. Apt, D., Raviprakash, K., Brinkman, A., Semyonov, A., Yang, S., Skinner, C., Diehl, L., Lyons, R., Porter, K. & Punnonen, J. (2006). Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24, 335-344.
3. Azevedo, A. S., Yamamura, A. M., Freire, M. S., Trindade, G. F., Bonaldo, M., Galler, R. & Alves, A. M. (2011). DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PLoS One 6, e20528.
4. Bäck, A. T. & Lundkvist, A. (2013). Dengue viruses - an overview. Infect Ecol Epidemiol 3, 19839.
5. Beckett, D., Kovaleva, E. & Schatz, P. J. (1999). A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 8, 921-929.
6. Beckett, C. G., Tjaden, J., Burgess, T., Danko, J. R., Tamminga, C., Simmons, M., Wu, S. J., Sun, P., Kochel, T. & other authors (2011). Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29, 960-968.
7. Benvenuti, F. & Burrone, O. R. (2001). Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants. Gene Ther 8, 1555-1561.
8. Butrapet, S., Childers, T., Moss, K. J., Erb, S. M., Luy, B. E., Calvert, A. E., Blair, C. D., Roehrig, J. T. & Huang, C. Y. (2011). Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology 413, 118-127.
9. Cesco-Gaspere, M., Benvenuti, F. & Burrone, O. R. (2005). BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunol Immunother 54, 351-358.
10. Coban, C., Kobiyama, K., Aoshi, T., Takeshita, F., Horii, T., Akira, S. & Ishii, K. J. (2011). Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 11, 479-484.
11. Coller, B. A., Clements, D. E., Bett, A. J., Sagar, S. L. & Ter Meulen, J. H. (2011). The development of recombinant subunit envelopebased vaccines to protect against dengue virus induced disease. Vaccine 29, 7267-7275.
12. Crill, W. D. & Roehrig, J. T. (2001). Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75, 7769-7773.
13. Danko, J. R., Beckett, C. G. & Porter, K. R. (2011). Development of dengue DNA vaccines. Vaccine 29, 7261-7266.
14. De Paula, S. O., Lima, D. M., de Oliveira França, R. F., Gomes-Ruiz, A. C. & da Fonseca, B. A (2008). A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge. Arch Virol 153, 2215-2223.
15. de Souza, V. A., Fernandes, S., Arauújo, E. S., Tateno, A. F., Oliveira, O. M., Oliveira, R. R. & Pannuti, C. S. (2004). Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. J Clin Microbiol 42, 1782-1784.
16. de Wispelaere, M. & Yang, P. L. (2012). Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly. J Virol 86, 7072-7083.
17. Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T. & other authors (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748.
18. Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. & other authors (2015). A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16, 170-177.
19. Erb, S. M., Butrapet, S., Moss, K. J., Luy, B. E., Childers, T., Calvert, A. E., Silengo, S. J., Roehrig, J. T., Huang, C. Y. & Blair, C. D. (2010). Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes. Virology 406, 328-335.
20. Galula, J. U., Shen, W. F., Chuang, S. T., Chang, G. J. & Chao, D. Y. (2014). Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol 88, 10813-10830.
21. Ge, P. & Zhou, Z. H. (2014). Chaperone fusion proteins aid entropydriven maturation of class II viral fusion proteins. Trends Microbiol 22, 100-106.
22. Graham, B. S., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K. & other authors (2006). Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194, 1650-1660.
23. Gromowski, G. D., Barrett, N. D. & Barrett, A. D. (2008). Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82, 8828-8837.
24. Gulland, A. (2013). Burden of dengue fever is higher than previously thought. BMJ 347, f6280.
25. Guzmán, M. G., Rodríguez, R., Rodríguez, R., Hermida, L., Alvarez, M., Lazo, L., Muné, M., Rosario, D., Valdés, K. & other authors (2003). Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 69, 129-134, 13677367.
26. Hanke, T., Szawlowski, P. & Randall, R. E. (1992). Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol 73, 653-660.
27. Henchal, E. A., McCown, J. M., Burke, D. S., Seguin, M. C. & Brandt, W. E. (1985). Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg 34, 162-169.
28. Hon, H., Oran, A., Brocker, T. & Jacob, J. (2005). B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 174, 5233-5242.
29. Hsieh, S. C., Tsai, W. Y., Nerurkar, V. R. & Wang, W. K. (2014). Characterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein. PLoS One 9, e100641.
30. Khan, K. H. (2013). DNA vaccines: roles against diseases. Germs 3, 26-35.
31. Khanam, S., Khanna, N. & Swaminathan, S. (2006). Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24, 6513-6525.
32. Klein, D. E., Choi, J. L. & Harrison, S. C. (2013). Structure of a dengue virus envelope protein late-stage fusion intermediate. J Virol 87, 2287-2293.
33. Konishi, E., Kosugi, S. & Imoto, J. (2006). Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24, 2200-2207.
34. Ledgerwood, J. E., Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M. & other authors (2011). A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 203, 1396-1404.
35. Li, E., Pedraza, A., Bestagno, M., Mancardi, S., Sanchez, R. & Burrone, O. (1997). Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng 10, 731-736.
36. Li, L., Lok, S. M., Yu, I. M., Zhang, Y., Kuhn, R. J., Chen, J. & Rossmann, M. G. (2008). The flavivirus precursor membraneenvelope protein complex: structure and maturation. Science 319, 1830-1834.
37. Li, X., Cao, H., Wang, Q., Di, B., Wang, M., Lu, J., Pan, L., Yang, L., Mei, M. & other authors (2012). Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice. Microbes Infect 14, 1000-1007.
38. Liao, M., Sánchez-San Martín, C., Zheng, A. & Kielian, M. (2010). In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein. J Virol 84, 5730-5740.
39. Lima, D. M., de Paula, S. O., França, R. F., Palma, P. V., Morais, F. R., Gomes-Ruiz, A. C., de Aquino, M. T. & da Fonseca, B. A. (2011). A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine 29, 831-838.
40. Lin, H. E., Tsai, W. Y., Liu, I. J., Li, P. C., Liao, M. Y., Tsai, J. J., Wu, Y. C., Lai, C. Y., Lu, C. H. & other authors (2012). Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis 6, e1447.
41. Lindenbach, B. D., Heinz-Jurgen, T. & Rice, C. M. (2007). Flaviviridae: the viruses and their replication. In Fields’ Virology, 5th edn., pp. 1126-1131. Edited by D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott-Raven.
42. Lok, S. M., Kostyuchenko, V., Nybakken, G. E., Holdaway, H. A., Battisti, A. J., Sukupolvi-Petty, S., Sedlak, D., Fremont, D. H., Chipman, P. R. & other authors (2008). Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15, 312-317.
43. MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J. & other authors (1998). First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178, 92-100.
44. Mani, S., Tripathi, L., Raut, R., Tyagi, P., Arora, U., Barman, T., Sood, R., Galav, A., Wahala, W. & other authors (2013). Pichia pastorisexpressed dengue 2 envelope forms virus-like particles without premembrane protein and induces high titer neutralizing antibodies. PLoS One 8, e64595.
45. Martin, J. E., Sullivan, N. J., Enama, M. E., Gordon, I. J., Roederer, M., Koup, R. A., Bailer, R. T., Chakrabarti, B. K., Bailey, M. A. & other authors (2006). A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13, 1267-1277.
46. Martin, J. E., Pierson, T. C., Hubka, S., Rucker, S., Gordon, I. J., Enama, M. E., Andrews, C. A., Xu, Q., Davis, B. S. & other authors (2007). A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196, 1732-1740.
47. Matsui, K., Gromowski, G. D., Li, L., Schuh, A. J., Lee, J. C. & Barrett, A. D. (2009). Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384, 16-20.
48. Modis, Y. (2014). Relating structure to evolution in class II viral membrane fusion proteins. Curr Opin Virol 5, 34-41.
49. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. (2005). Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79, 1223-1231.
50. Monath, T. P., Arroyo, J., Levenbook, I., Zhang, Z. X., Catalan, J., Draper, K. & Guirakhoo, F. (2002). Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol 76, 1932-1943.
51. Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. (2005). A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13-22.
52. Murray, N. E., Quam, M. B. & Wilder-Smith, A. (2013). Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5, 299-309.
53. Naish, S., Dale, P., Mackenzie, J. S., McBride, J., Mengersen, K. & Tong, S. (2014). Climate change and dengue: a critical and systematic review of quantitative modelling approaches. BMC Infect Dis 14, 167.
54. Ninth Report of the International Committee on Taxonomy of Viruses (2012). Family-Flaviviridae. In Virus Taxonomy, pp. 1003-1020. Edited by A. M. Q. King, M. J. Adams, E. B. Carstens & E. J. San Diego: Elsevier Science.
55. Ocazionez Jimenez, R. & Lopes da Fonseca, B. A. (2000). Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 19, 648-654.
56. Petris, G., Bestagno, M., Arnoldi, F. & Burrone, O. R. (2014). New tags for recombinant protein detection and O-glycosylation reporters. PLoS One 9, e96700.
57. Pierson, T. C., Fremont, D. H., Kuhn, R. J. & Diamond, M. S. (2008). Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4, 229-238.
58. Poggianella, M., Slon Campos, J. L., Chan, K. R., Tan, H. C., Bestagno, M., Ooi, E. E. & Burrone, O. R. (2015). Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes. PLoS Negl Trop Dis 9, e0003947.
59. Predonzani, A., Arnoldi, F., Loúpez-Requena, A. & Burrone, O. R. (2008). In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol 8, 41.
60. Prompetchara, E., Ketloy, C., Keelapang, P., Sittisombut, N. & Ruxrungtham, K. (2014). Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines. PLoS One 9, e92643.
61. Ramanathan, M. P., Kuo, Y. C., Selling, B. H., Li, Q., Sardesai, N. Y., Kim, J. J. & Weiner, D. B. (2009). Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 27, 6444-6453.
62. Raviprakash, K., Kochel, T. J., Ewing, D., Simmons, M., Phillips, I., Hayes, C. G. & Porter, K. R. (2000). Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18, 2426-2434.
63. Raviprakash, K., Marques, E., Ewing, D., Lu, Y., Phillips, I., Porter, K. R., Kochel, T. J., August, T. J., Hayes, C. G. & Murphy, G. S. (2001). Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GMCSF. Virology 290, 74-82.
64. Raviprakash, K., Apt, D., Brinkman, A., Skinner, C., Yang, S., Dawes, G., Ewing, D., Wu, S. J., Bass, S. & other authors (2006). A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353, 166-173.
65. Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298.
66. Rodenhuis-Zybert, I. A., van der Schaar, H. M., da Silva Voorham, J. M., van der Ende-Metselaar, H., Lei, H. Y., Wilschut, J. & Smit, J. M. (2010). Immature dengue virus: a veiled pathogen? PLoS Pathog 6, e1000718.
67. Rothman, A. L. (2011). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11, 532-543.
68. Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., Duquerroy, S., Vaney, M. C., Kikuti, C. M., Navarro Sanchez, M. E., Dejnirattisai, W., Wongwiwat, W. & other authors (2015). Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109-113.
69. Saenz, R., Messmer, B., Futalan, D., Tor, Y., Larsson, M., Daniels, G., Esener, S. & Messmer, D. (2014). Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical Cterminal portion and is enhanced by dimerization. Mol Immunol 57, 191-199.
70. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual. New York: Cold Spring Harbor Laboratory Press.
71. Sarwar, U. N., Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S. & other authors (2015). Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 211, 549-557.
72. Schibli, D. J. & Weissenhorn, W. (2004). Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol Membr Biol 21, 361-371.
73. Shedlock, D. J. & Weiner, D. B. (2000). DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 68, 793-806.
74. Simmons, C. P., Farrar, J. J., Nguyen, V. & Wills, B. (2012). Dengue. N Engl J Med 366, 1423-1432.
75. Sukupolvi-Petty, S., Austin, S. K., Engle, M., Brien, J. D., Dowd, K. A., Williams, K. L., Johnson, S., Rico-Hesse, R., Harris, E. & other authors (2010). Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84, 9227-9239.
76. Tsai, W. Y., Hsieh, S. C., Lai, C. Y., Lin, H. E., Nerurkar, V. R. & Wang, W. K. (2012). C-terminal helical domains of dengue virus type 4 E protein affect the expression/stability of prM protein and conformation of prM and E proteins. PLoS One 7, e52600.
77. Vaughn, D. W., Scherer, J. M. & Sun, W. (2008). Resistance to infection. In Dengue, pp. 123-169. Edited by S. B. Halstead. London: Imperial College Press.
78. Wahala, W. M. & Silva, A. M. (2011). The human antibody response to dengue virus infection. Viruses 3, 2374-2395.
79. Wahala, W. M., Kraus, A. A., Haymore, L. B., Accavitti-Loper, M. A. & de Silva, A. M. (2009). Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392, 103-113.
80. Weaver, S. C. & Vasilakis, N. (2009). Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol 9, 523-540.
81. WHO (2009). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization Press.
82. Williams, K. L., Wahala, W. M., Orozco, S., de Silva, A. M. & Harris, E. (2012). Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429, 12-20.
83. Zhang, W., Chipman, P. R., Corver, J., Johnson, P. R., Zhang, Y., Mukhopadhyay, S., Baker, T. S., Strauss, J. H., Rossmann, M. G. & Kuhn, R. J. (2003). Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10, 907-912.
84. Zhang, Y., Zhang, W., Ogata, S., Clements, D., Strauss, J. H., Baker, T. S., Kuhn, R. J. & Rossmann, M. G. (2004). Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618.
85. Zheng, A., Umashankar, M. & Kielian, M. (2010). In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions. PLoS Pathog 6, e1001157.
86. Zompi, S., Santich, B. H., Beatty, P. R. & Harris, E. (2012). Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 188, 404-416.